Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in pediatric moderate to severe active ulcerative colitis
CTR20260936Phase 3Active
- Sponsor
- Roche
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of afimkibart in autoimmune colitis, sponsored by Roche. Started Apr 2026; status: active.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20260936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260936.